Navigation Links
Clinical Trial for the Treatment of Inflammatory Bowel Disease Begins at Tel Aviv Sourasky Medical Center
Date:7/21/2008

Anadis Ltd (ASX:ANX; OTC:ANDIY), a biopharmaceutical company focused on research, development and production of immune milk (colostrum)-derived polyclonal antibodies and other proteins to address major diseases, today announces the initiation of a clinical trial with top clinical scientists at Tel Aviv Sourasky Medical Center in Israel. The clinical trial will explore the efficacy of a formulation developed by Anadis to address the symptoms of Inflammatory Bowel Disease (IBD), a serious chronic condition effecting millions of persons annually.

MELBOURNE, Australia (Business Wire EON) July 21, 2008 -- About 4 million people worldwide suffer from Inflammatory Bowel Disease, split roughly evenly between the two manifestations of the disease: Crohn's disease (CD) and ulcerative colitis (UC). IBD is a relapsing / remitting chronic disease with gastrointestinal symptoms such as diarrhoea, rectal bleeding and abdominal pain.

The study is led by a leading Israeli Gastroenterologist, Professor Zamir Halpern, Deputy Director of Tel Aviv Sourasky Medical Center and Chief of the Center's Gastroenterology Institute, and by Professor Nachum Vaisman, Head of the Unit of Clinical Nutrition.

The first patients have already been recruited and have entered the trial which is expected be completed during 2009. The trial is designed as an open study being run to confirm and expand upon human clinical data obtained from a pilot study at St Vincent's Hospital in Melbourne, which ended recently. Anadis intends to launch its colostrum-derived product as a medical food or nutritional immediately following the Tel Aviv trial. Anadis will meet all regulatory requirements during the conduct of the trial itself.

In addition to the initiation of this IBD study, Anadis recently announced being awarded a VISTECH grant for another study, also to be conducted at Tel Aviv Souraski Medical Center, towards the development and commercialization of a product to address cancer-related mucositis. See "Anadis Awarded VISTECH grant for Clinical Trial of Polyclonal Antibodies for the Treatment of Cancer Related Mucositis" - Tuesday 1 July 2008."

Tel Aviv Sourasky Medical Center (TASMC) is one of the largest hospitals in Israel with 1100 beds and is responsible for providing specialty care to the Tel Aviv metropolitan area. It is a teaching and research center affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dr Oren Fuerst, VP Business development of Anadis stated, "This is another illustration of the successful collaboration between Anadis and the researchers at TASMC. The leveraging of Australian manufacturing and core research, with research and clinical studies in Israel will allow us to bring products to market faster and at lower costs than otherwise. Our current plans calls for commercialization of both the IBD and the mucositis products within less than 2 years, addressing two major gastrointestinal diseases using our core platform."

Read the full story at http://www.prweb.com/releases/tel_aviv/anadis/prweb1132164.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
2. North Carolinas Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center
3. Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes
4. Northwestern Memorial Among Americas Best Hospitals in 10 Clinical Specialties According to U.S. News 2008 Rankings
5. Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
6. Termination of IS Clinical From Distributing PhytoCeuticals Formulas
7. Dr. Howard Epstein Joins Blue Cross as Medical Director for Commercial Operations and Clinical Design
8. Award-Winning Massachusetts Hospital Selects MedQuist Enterprise Technology for Clinical Documentation and Speech Recognition
9. Clinical Launch of Innovative Cloth Sleep Apnea Mask Creates Buzz at Sleep Conference
10. New clinical trial for patients with asbestos-associated lung cancer
11. Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
Breaking Medicine Technology: